Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Nimrata HuntEVP | Idexx LaboratoriesIDXX | Open-market sale | 03/03 | 03/05 | 1,758 sh | $634.57 | $1,115,574.06 | −8.8% |
Idexx LaboratoriesIDXX | Open-market sale | 02/26 | 03/02 | 23,326 sh13 trades | $657.55avg. | $15,338,088.6 | −21.8% | |
Nimrata HuntEVP | Idexx LaboratoriesIDXX | Open-market sale | 02/26 | 02/27 | 2,693 sh | $661.54 | $1,781,527.22 | −11.9% |
Idexx LaboratoriesIDXX | Open-market sale | 02/17 | 02/19 | 1,464 sh2 trades | $628.62avg. | $920,296.89 | −69.3% | |
Idexx LaboratoriesIDXX | Open-market sale | 02/17 | 02/19 | 5,371 sh6 trades | $627.38avg. | $3,369,668.49 | −29.7% | |
Idexx LaboratoriesIDXX | Open-market sale | 02/10 | 02/11 | 11,345 sh8 trades | $646.72avg. | $7,337,011.27 | −53.6% | |
Idexx LaboratoriesIDXX | Open-market sale | 25/11/07 | 25/11/10 | 9,425 sh4 trades | $703.34avg. | $6,628,998.53 | −30.8% | |
M. Anne SzostakDirector | Idexx LaboratoriesIDXX | Open-market sale | 25/08/22 | 25/08/26 | 2,187 sh | $647.33 | $1,415,710.71 | −89.3% |
Idexx LaboratoriesIDXX | Open-market sale | 25/08/12 | 25/08/14 | 405.89 sh2 trades | $649.96avg. | $263,812.14 | −3.5% | |
Nimrata HuntEVP | Idexx LaboratoriesIDXX | Open-market sale | 25/08/11 | 25/08/13 | 1,200 sh | $656.53 | $787,836 | −6.7% |
Sharon E. UnderbergEVP, GC & Corporate Secretary | Idexx LaboratoriesIDXX | Open-market sale | 25/08/08 | 25/08/12 | 5,450 sh | $651.60 | $3,551,220 | −47.0% |
Idexx LaboratoriesIDXX | Open-market sale | 25/08/06 | 25/08/08 | 29,260 sh10 trades | $631.98avg. | $18,491,630.9 | −26.0% | |
Idexx LaboratoriesIDXX | Open-market sale | 25/08/06 | 25/08/08 | 8,411 sh3 trades | $627.73avg. | $5,279,872.56 | −54.1% | |
Idexx LaboratoriesIDXX | Open-market sale | 25/08/06 | 25/08/08 | 7,143 sh3 trades | $630.43avg. | $4,503,183.45 | −28.4% | |
Idexx LaboratoriesIDXX | Open-market sale | 25/05/21 | 25/05/23 | 2,306 sh2 trades | $512.98avg. | $1,182,920.44 | No record | |
Daniel M. JuniusDirector | Idexx LaboratoriesIDXX | Open-market sale | 25/05/13 | 25/05/14 | 2,683 sh | $506.41 | $1,358,698.03 | −44.8% |
Sophie V. VandebroekDirector | Idexx LaboratoriesIDXX | Open-market sale | 25/05/09 | 25/05/13 | 1,279 sh | $491.34 | $628,423.86 | −52.3% |
Idexx LaboratoriesIDXX | Open-market sale | 25/02/10 | 25/02/11 | 9,986 sh | $462.53 | $4,618,824.58 | −55.0% | |
M. Anne SzostakDirector | Idexx LaboratoriesIDXX | Open-market sale | 25/02/07 | 25/02/10 | 3,000 sh | $465.95 | $1,397,850 | −49.5% |
Sophie V. VandebroekDirector | Idexx LaboratoriesIDXX | Open-market sale | 24/11/27 | 24/11/29 | 344 sh | $420.44 | $144,631.36 | −27.5% |